Página InicialGruposDiscussãoMaisZeitgeist
Pesquisar O Sítio Web
Este sítio web usa «cookies» para fornecer os seus serviços, para melhorar o desempenho, para analítica e (se não estiver autenticado) para publicidade. Ao usar o LibraryThing está a reconhecer que leu e compreende os nossos Termos de Serviço e Política de Privacidade. A sua utilização deste sítio e serviços está sujeita a essas políticas e termos.

Resultados dos Livros Google

Carregue numa fotografia para ir para os Livros Google.

Bad Blood: Secrets and Lies in a Silicon…
A carregar...

Bad Blood: Secrets and Lies in a Silicon Valley Startup (original 2018; edição 2020)

por John Carreyrou (Autor)

MembrosCríticasPopularidadeAvaliação médiaMenções
2,7481875,374 (4.31)97
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.… (mais)
Membro:marshapetry
Título:Bad Blood: Secrets and Lies in a Silicon Valley Startup
Autores:John Carreyrou (Autor)
Informação:Vintage (2020), Edition: New, 368 pages
Coleções:A sua biblioteca
Avaliação:
Etiquetas:Nenhum(a)

Informação Sobre a Obra

Bad Blood: Secrets and Lies in a Silicon Valley Startup por John Carreyrou (2018)

Adicionado recentemente porNonennui, ghm85, SamGon02, ClimateBabs, jainil, trelarosa, biblioteca privada, InkandQuill, BroraRuth
A carregar...

Adira ao LibraryThing para descobrir se irá gostar deste livro.

Ainda não há conversas na Discussão sobre este livro.

» Ver também 97 menções

Inglês (184)  Sueco (1)  Todas as línguas (185)
Mostrando 1-5 de 185 (seguinte | mostrar todos)
BIBLIOGRAPHIC DETAILS:
(Available as Print: ©5/21/2018; PUBLISHER: Knopf; ISBN: 978-1524731656; PAGES: 352; Unabridged.)
(Available as Digital: Yes)

*This version: Audio : ©5/21/2018; PUBLISHER: Penguin Random House Audio Publishing Group; DURATION: 11:41:54; FILE SIZE: 334544 KB; Unabridged

(Feature Film or tv: There is a documentary as well as a film version that is In the making.)

Series: No

SUMMARY/ EVALUATION:
I saw the print version of this while in my favorite bookstore, Newport Beach Public Library’s Friends Used Books, and overheard a fellow-patron who’d spotted it as well, telling the volunteers how thoroughly he enjoyed this book. Indeed, he claimed it was his all-time favorite (and this fellow was around MY age, no Spring chicken). He was asking the volunteer if she was familiar with it and with the case that was currently in the news which the book focuses on. The volunteer was aware, but wasn’t interested in hearing about the book. I got a sense of disapproval on her part, but of what (Book? Author? Biographee?) Anyway, I made a mental note to check my Los Angeles Public Library’s (LAPL) Overdrive for the audio version, and, when I did, was thrilled to find I didn’t even need to place a hold. . . .not for the first check-out. By the time I needed to renew it however, I would have, had I not been rescued by my other favorite library’s (Palos Verdes Library District) Overdrive. I suspect by this time the news had been more regularly airing snippets and the fact that a verdict on the Elizabeth Holmes/Theranos trial was going to run over into the new year.
Even if you have no interest in medical devices/technology; business, startup companies, or white collar crime, this book is fascinating, not to mention exceedingly well written.

AUTHOR:
John Carreyrou: According to Wikipedia, “John Carreyrou (/ˌkæriˈruː/)[1] is a French-American journalist and writer who worked for The Wall Street Journal for 20 years between 1999 and 2019[2] and has been based in Brussels, Paris, and New York City. He has won the Pulitzer Prize twice and is well known for having exposed the fraudulent practices of the multibillion-dollar blood-testing company Theranos in a series of articles published in the Wall Street Journal. . . . A book-length treatment titled Bad Blood: Secrets and Lies in a Silicon Valley Startup (2018)[34] won the Financial Times and McKinsey Business Book of the Year Award.[35] A film version is in the works starring Jennifer Lawrence, written by Vanessa Taylor, and directed by Adam McKay.[36] . . .”

NARRATOR:
Will Damron: According to Tantor Media, “Will Damron is an Audie Award–nominated narrator who has recorded books in every genre, from science fiction and fantasy to romance, YA, and nonfiction. Raised in rural southern Virginia, he has appeared Off-Broadway and on stage and screen throughout the country. He lives in Los Angeles, California.”
VERY good narration here.

GENRE:
Biography; Biography; Nonfiction; Technology

LOCATIONS:
Palo Alto

TIME FRAME:
2003-2018

SUBJECTS:
Family; Start-ups; Nepotism; Business; Medical Devices; Labs; Blood tests; fraud; criminal; politicians; celebrities; marketing; Theranos (firm) history; hematologic equipment; industry; Economics; Entrepreneurship; Finance; Biomedical; technology and engineering; trade secrets; whistle blowers; Elizabeth Holmes; deceit; management; ambition; venture capital

DEDICATION:
I didn’t see one in the digital sample on Amazon.

SAMPLE QUOTATION:
From the Prologue
"November 17, 2006
Tim Kemp had good news for his team.
The former IBM executive was in charge of bioinformatics at Theranos, a startup with a cutting-edge blood-testing system. The company had just completed its first big live demonstration for a pharmaceutical company. Elizabeth Holmes, Theranos's twenty-two-year-old founder, had flown to Switzerland and shown off the system's capabilities to executives at Noartis, the European drug giant.
'Elizabeth called me this morning,' Kemp wrote in an email to his fifteen-person team. 'She expressed her thanks and said that, 'it went perfect!' She specifically asked me to thank you and let you all know her appreciation. She additionally mentioned that Novartis was so impressed that they have asked for a proposal and have expressed interest in a financial arrangement for a project. We did what we came to do!'
This was a pivotal moment for Theranos. The three-year-old startup had progressed from an ambitious idea Holmes had dreamed up in her Stanford dorm room to an actual product a huge multinational corporation was interested in using.
Word of the demo's success made its way upstairs to the second floor, where senior executives offices were located.
One of those executives was Henry Mosley, Theranos's chief financial officer. Mosley had jointed Theranos eight months earlier, in March, 2006. A rumpled dresser with piercing green eyes and a laid-back personality, he was a veteran of Silicon Valley's technology scene. . . ."

RATING:
5 stars. GREAT book.

STARTED READING – FINISHED READING
12/27/2021 – 1/25/2022 ( )
  TraSea | Apr 29, 2024 |
Surprisingly readable investigative story. I was worried that there would be too many characters to keep track of, but each chapter concentrates on a certain group that then disappears from focus (often because they get fired).
( )
  Levitara | Apr 5, 2024 |
This is an incredible expose about Elizabeth Holmes, 20 years old, college drop out before sophomore year, charismatic and with a desire for "a purposeful life". She patented her idea to develop an in-home mini lab where individuals can administer their own blood test with a single drop of blood and transfer the info to their doctor for treatment recommendations, if necessary.
In the span of 10 years Theranos, the start-up which Holmes created, went from a little blood testing machine to, well, a little non-functioning blood testing machine. Through quick thinking, being evasive and using outside testing facilities for accurate results was she was able to receive the backing of the US Army and former Secretaries of State, George Schultz and Henry Kissinger.
How does this flimsy start-up come to an end? A phone call to a Wall Street Journal journalist named John Carryrou from a suspicious employee. ( )
  Carmenere | Apr 2, 2024 |
Highly informative and interesting. Could barely put it down. Simply fantastic. ( )
  guildlingsfan | Mar 28, 2024 |
The thing about this being a page-turner was no joke: i read it in three days. ( )
  aleshh | Jan 12, 2024 |
Mostrando 1-5 de 185 (seguinte | mostrar todos)
The author’s description of Holmes as a manic leader who turned coolly hostile when challenged is ripe material for a psychologist; Carreyrou wisely lets the evidence speak for itself. As presented here, Holmes harbored delusions of grandeur but couldn’t cope with the messy realities of bioengineering. Swathed in her own reality distortion field, she dressed in black turtlenecks to emulate her idol Jobs and preached that the Theranos device was “the most important thing humanity has ever built.” Employees were discouraged from questioning this cultish orthodoxy by her “ruthlessness” and her “culture of fear.” Secrecy was obsessive. Labs and doors were equipped with fingerprint scanners.
adicionada por danielx | editarNew York Times, Roger Lowenstein (Jan 6, 2018)
 

» Adicionar outros autores

Nome do autorPapelTipo de autorObra?Estado
John Carreyrouautor principaltodas as ediçõescalculado
Damron, WillNarradorautor secundárioalgumas ediçõesconfirmado
Tem de autenticar-se para poder editar dados do Conhecimento Comum.
Para mais ajuda veja a página de ajuda do Conhecimento Comum.
Título canónico
Título original
Títulos alternativos
Data da publicação original
Pessoas/Personagens
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Locais importantes
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Acontecimentos importantes
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Filmes relacionados
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Epígrafe
Dedicatória
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
For Molly, Sebastian, Jack, and Francesca
Primeiras palavras
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Tim Kemp had good news for his team.
Citações
Últimas palavras
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
(Carregue para mostrar. Atenção: Pode conter revelações sobre o enredo.)
Nota de desambiguação
Editores da Editora
Autores de citações elogiosas (normalmente na contracapa do livro)
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Língua original
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
DDC/MDS canónico
LCC Canónico

Referências a esta obra em recursos externos.

Wikipédia em inglês

Nenhum(a)

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.

Não foram encontradas descrições de bibliotecas.

Descrição do livro
Resumo Haiku

Current Discussions

Nenhum(a)

Capas populares

Ligações Rápidas

Avaliação

Média: (4.31)
0.5
1 10
1.5
2 8
2.5 1
3 81
3.5 33
4 338
4.5 70
5 398

É você?

Torne-se num Autor LibraryThing.

 

Acerca | Contacto | LibraryThing.com | Privacidade/Termos | Ajuda/Perguntas Frequentes | Blogue | Loja | APIs | TinyCat | Bibliotecas Legadas | Primeiros Críticos | Conhecimento Comum | 208,662,440 livros! | Barra de topo: Sempre visível